Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report
Akums Drugs and Pharmaceuticals Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 7:54 pm
Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report CRISIL Ratings issued its final monitoring agency report for Akums Drugs and Pharmaceuticals Ltd. for the quarter ended 30th Sep'26, confirming 100% utilization of its Rs 6,800.00 mn gross IPO proceeds (revised net proceeds of Rs 6,421.80 mn). Key deployments include Rs 3,870.00 mn toward debt repayment for the company and subsidiaries, Rs 550.00 mn for incremental working capital, Rs 301.80 mn for inorganic acquisitions, and Rs 1,700.00 mn for general corporate purposes. With zero unutilized proceeds remaining, future quarterly monitoring submissions are no longer required.
Original exchange filing (PDF)
More announcements from Akums Drugs and Pharmaceuticals Ltd
- Intimation of Schedule of the Investors/Analysts Meet 路 10 Nov 2026
- Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 路 05 Nov 2026
- Audio recording of Earning/ Quarterly Conference Call 路 03 Nov 2026
- Newspaper Publication 路 03 Nov 2026
- Q2 FY 2026-27 - Investor Presentation 路 02 Nov 2026
- Press Release 路 02 Nov 2026
- Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company. 路 02 Nov 2026
- Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management 路 02 Nov 2026
